Ruxolitinib - PDFSEARCH.IO - Document Search Engine

Ruxolitinib
Results: 17

#	Item
1	SUPPLEMENTARY INFORMATION: Specificity and mechanism-‐ of-‐action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) 1. Deter Add to Reading List Source URL: www.biochem-caflisch.uzh.ch - Date: 2014-03-12 10:03:01
2	HAEMATOLOGY AUDIT TEMPLATE Add to Reading List Source URL: www.bcshguidelines.com Language: English - Date: 2015-09-20 08:20:56 Myelofibrosis Janus kinase inhibitor Splenomegaly Myeloproliferative neoplasm Ruxolitinib Medical diagnosis Polycythemia vera
3	Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard Add to Reading List Source URL: www.promedior.com Language: English - Date: 2015-02-08 17:25:15 Myelofibrosis Essential thrombocytosis Myeloproliferative disease Plateletpheresis Ruxolitinib Megakaryocyte Platelet Bone marrow Anemia Medicine Biology Anatomy
4	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca Add to Reading List Source URL: www.novartis.ca Language: English - Date: 2015-05-13 10:22:06 Myelofibrosis Janus kinase inhibitor Essential thrombocytosis Thrombocytosis Splenomegaly Polycythemia vera Myeloproliferative disease Thrombocytopenia TG101348 Medicine Hematopathology Ruxolitinib
5	PDF Document Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2014-10-01 21:56:24 Medical statistics Design of experiments Evaluation methods Ruxolitinib Essential thrombocytosis Polycythemia vera Myelofibrosis Thrombocytosis Clinical trial Medicine Pharmacology Clinical research
6	Statement of Advice ruxolitinib (Jakavi®) 5mg, 15mg and 20mg Tablets Novartis Pharmaceuticals UK Ltd (No: 867/13) Add to Reading List Source URL: www.scottishmedicines.org.uk Language: English NHS Scotland Pharmacology Pharmacy Clinical pharmacology Scottish Medicines Consortium Myelofibrosis Ruxolitinib Pharmaceuticals policy Formulary Medicine Health Pharmaceutical sciences
7	PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer Add to Reading List Source URL: pbs.gov.au Language: English - Date: 2015-03-12 23:53:04 Pharmaceutical Benefits Scheme Pharmacology Myelofibrosis International Prognostic Scoring System IPSS Clinical trial Medicine Health Ruxolitinib
8	PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer representa Add to Reading List Source URL: pbs.gov.au Language: English - Date: 2015-03-12 23:53:04 Pharmaceutical Benefits Scheme Pharmacology Myelofibrosis International Prognostic Scoring System IPSS Clinical trial Medicine Health Ruxolitinib
9	July 2014 PBAC OUTCOMES - Deferrals Drug Name, form(s), strength(s), Sponsor, Type of submission Drug Type and Use Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2015-01-19 17:21:09 Pharmacology Medicine Healthcare in Australia Pharmaceutical Benefits Scheme Pharmaceuticals policy Health Ruxolitinib Infliximab Ustekinumab Immunosuppressants Centocor Monoclonal antibodies
10	ruxolitinib (as phosphate), 5mg, 15mg, & 20mg tablets (Jakavi®) SMC No[removed]Novartis Pharmaceuticals UK Ltd. 06 February 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above produc Add to Reading List Source URL: www.scottishmedicines.org.uk Language: English Janus kinase inhibitor Placebo Thrombocytosis Polycythemia vera Splenomegaly Leukemia Medicine Ruxolitinib Myelofibrosis